GIKLY Grifols S.A. Sponsored ADRs Class A

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain. This is an ADR of a company whose stock trades outside of the U.S. as the symbol SM:GRF.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$11.64    Pink
As of 10/22/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  Spain
Country of incorporation:  Spain
IPO date:  05/27/2009
Outstanding shares:  852,259,596
Average volume:  0
Market cap:   $3,625,964,750
Current dividend yield:  2.94%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    398438200
ISIN:        US3984382008
Sedol:      
Valuation   (See tab for details)
PE ratio:   19.74
PB ratio:   4.08
PS ratio:   0.70
Return on equity:   14.66%
Net income %:   14.57%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy